Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma

Cancer Science

Volumn 97, Issue 12, 2006, Pages 1410-1416

  Watanabe, Junichi ^a   Natsume, Tsugitaka ^a   Kobayashi, Motohiro ^a  

^a Grelan Pharmaceutical Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURISTATIN PE; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER STAGING; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOGENESIS; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELLS, CULTURED; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GUINEA PIGS; HUMANS; MICE; MICE, INBRED BALB C; MICROTUBULES; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; SKIN; UMBILICAL VEINS;

EID: 33750372682     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00330.x     Document Type: Article

References (38)

1. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res 1989; 49: 6449-65.
2. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-96.
3. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990; 9: 267-82.
4. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000; 10: 435-42.
5. St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-202.
6. Bibby MC, Double JA, Loadman PM, Duke CV. Reduction of tumor blood flow by flavone acetic acid: A possible component of therapy. J Natl Cancer Inst 1989; 81: 216-20.
7. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst 1989;81: 1005-13.
8. Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995; 36: 143-8.
9. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-34.
10. Tozer GM, Prise VE, Wilson J et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999; 59: 1626-34.
11. Blakey DC, Westwood FR, Walker M et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8: 1974-83.
12. Davis PD, Dougherty GJ, Blakey DC et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62: 7247-53.
13. Nihei Y, Suga Y, Morinaga Y et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999; 90: 1016-25.
14. Hill SA, Toze GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002; 22: 1453-8.
15. Miyazaki K, Kobayashi M, Natsume T et al. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 1995; 43: 1706-18.
16. Natsume T, Watanabe J, Fujio N, Miyasaka K, Kobayashi M. Characterization of the interaction of TZT-1027a potent antitumor agent with tubulin. Jpn J Cancer Res 2000; 91: 737-47.
17. Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 2000; 5: 345-53.
18. Natsume T, Koh Y, Kobayashi M et al. Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo. Cancer Chemother Pharmacol 2002; 49: 35-47.
19. Watanabe J, Minami M, Kobayashi M. Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res 2006; 26: 1973-82.
20. Kobayashi M, Natsume T, Tamaoki S et al. Antitumor activity of TZT-1027a novel dolastatin 10 derivative. Jpn J Cancer Res 1997; 88: 316-27.
21. Otani M, Natsume T, Watanabe J et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000; 91: 837-44.
22. Galbraith SM, Chaplin DJ, Lee F et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001; 21: 93-102.
23. Micheletti G, Poli M, Borsotti P et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003; 63: 1534-7.
24. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: A novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002; 54: 1497-502.
25. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abott BJ. Protocols for Screening Chemical Agents and Natural Products Against Animal Tumor and Other Biochemical Systems. Cancer Chemother Rep, 1972; 3: 1-103.
26. Lal BK, Varma S, Pappas PJ, Hobson RW 2nd, Duran WN. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 2001; 62: 252-62.
27. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002; 99: 2060-9.
28. Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 71: 1204-9.
29. Natsume T, Watanabe J, Koh Y et al. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci 2003; 94: 826-33.
30. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482-7.
31. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29: 1320-4.
32. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19: 189-95.
33. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53: 164-71.
34. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005; 62: 846-53.
35. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99: 1-6.
36. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 2004; 10: 7671-6.
37. Bilenker JH, Flaherty KT, Rosen M et al. Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 2005; 11: 1527-33.
38. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491-9.